Ballan v. Upjohn Co.

159 F.R.D. 473, 1994 U.S. Dist. LEXIS 19093, 1994 WL 735621
CourtDistrict Court, W.D. Michigan
DecidedDecember 29, 1994
DocketNo. 5:92-CV-9
StatusPublished
Cited by41 cases

This text of 159 F.R.D. 473 (Ballan v. Upjohn Co.) is published on Counsel Stack Legal Research, covering District Court, W.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ballan v. Upjohn Co., 159 F.R.D. 473, 1994 U.S. Dist. LEXIS 19093, 1994 WL 735621 (W.D. Mich. 1994).

Opinion

OPINION RE MOTION FOR CERTIFICATION OF CLASS

HILLMAN, Senior District Judge.

Before the court in this securities fraud case is plaintiff Thomas Acito’s motion for class certification. Plaintiff, a purchaser of defendant The Upjohn Company’s stock, alleges defendants: (1) violated Section 10(b) of the Securities and Exchange Act, and Rule 10b-5 promulgated thereunder; (2) violated Section 20 of the Securities and Exchange [477]*477Act; and (3) committed common law fraud and deceit. Defendants are The Upjohn Company (“Upjohn”), a pharmaceutical corporation headquartered in Kalamazoo, Michigan, as well as eight individuals who are Upjohn’s corporate directors and officers. Defendants oppose class certification, claiming plaintiffs case does not meet the requirements of Fed.R.Civ.P. 23. For the reasons stated below, plaintiffs motion is DENIED.

FACTS

Defendant Upjohn is the developer and manufacturer of the drug Haleion, a widely prescribed sleep medication. Technically known as triazolam, Haleion is a benzodiazepine compound which is unique because of its short half-life. Upjohn claims Haleion takes effect quickly, and then is metabolized quickly. Further, according to defendant, it helps the patient go to sleep, but does not leave the patient feeling drowsy the next morning. In practice, Haleion has been controversial because of the side effects it can produce. One court noted that “[ajccording to defendant Upjohn, the reported injuries have included amnesia ... vertigo ... hangover ... nervousness, insomnia, drowsiness ... attempted suicide ... hallucinations ... aggression, euphoria, headache ... and others.” Pasternak v. Upjohn Co., 92 CV 5987, unpub. op. at 2 (E.D.N.Y. September 19, 1994).

The primary factual issue in this case, however, is not whether Haleion users suffer side effects. The issue is whether defendants committed fraud on the stock market by allegedly concealing research data concerning Halcion’s side effects so as to inflate artificially the price of Upjohn’s stock.

After Haleion was first synthesized in 1969, it was subjected to numerous studies to determine its safety and effectiveness. Plaintiff claims that defendants deliberately manipulated test data in several of these studies to make Haleion appear safer and more effective than it actually is. Plaintiff asserts that defendants began this fraudulent practice in one of the very first clinical studies of Haleion, conducted in Michigan in 1972. Plaintiff states that in this study, known as Protocol 321, defendants intentionally under-reported the number of side effects suffered by study participants. Plaintiff states that in a second study, Protocol 6045, more than half of the study’s participants were enrolled by a doctor who was found by a Food and Drug Administration (“FDA”) investigation to have fabricated patient records and also to have failed to report adverse reactions. Pointing to a third study, Protocol 6415, plaintiff also accuses defendants of relying on test data falsified by the doctor who conducted the tests. Plaintiff states that in a fourth study, Protocol 9118, results from 188 out of 1,567 subjects were omitted without explanation.

Plaintiff contends that Upjohn, based on its fraudulent testing practices, obtained approval in 1977 to market'the drug in Belgium and the Netherlands at doses of up to 1 milligram. In 1979, however, the Netherlands banned the drug after having received approximately 1,100 reports from doctors citing serious side effects in patients who took Haleion.

In 1982, Haleion was licensed for sale in the United States for doses of up to 0.5 milligrams. Plaintiff states this approval was based in part on the inaccurate protocols noted above. In 1987, however, the license previously granted for the 0.5 milligram dose was suspended by France and Italy. Upjohn then lowered the recommended starting dose in the United States to 0.25 milligrams.

In addition to deceiving governmental drug regulators, plaintiff claims defendants also failed to disclose Halcion’s known adverse side effects to Upjohn’s stockholders. Plaintiff states defendants failed to disclose the truth about Haleion in Upjohn’s Annual Report to Shareholders for the fiscal year ending December 31, 1987, and in Upjohn’s Annual Report filed in March 1989 on Form 10-K for the year of 1988. Further, plaintiff claims defendants issued reports throughout the class period on Form 10-K and quarterly reports on Form 10-Q that were false and misleading.

Plaintiff alleges that defendants’ fraudulent testing practices were discovered as the result of a product liability action in Utah. The action was settled prior to trial. As part of the settlement, all documents produced in the case were to remain confidential. Plain[478]*478tiff states that nevertheless some of the documents produced were provided to the Committee on Safety of Medicines (“CSM”) in the United Kingdom (“UK”). On August 25, 1991, The Sunday Express, a British newspaper, reported that a spokesman for Upjohn’s British subsidiary, Upjohn UK, had admitted errors in a 1972 study conducted in Michigan. On August 28, 1991, The Washington Post reported that a spokesman for Upjohn had confirmed the presence of errors in the study. After undertaking a review of Halcion’s safety, the CSM announced by letter dated September 30, 1991, that Halcion sales would be suspended as of October 2, 1991. Plaintiff further alleges that subsequent to the UK suspension, sales of Halcion were banned in Finland, Norway, Argentina, Jamaica, and the Netherlands.

On January 20,1992, The New York Times ran a front page story entitled, “Maker of Sleeping Pill Hid Data On Side Effects, Researchers Say.” The article summarized many of the above claims. It also included portions of an interview with Dr. Ian Oswald, a Scottish psychiatrist, whom plaintiffs in the Utah product liability case had planned to call as an expert witness. In addition, it noted that in August of 1991, the FDA had begun an investigation of Upjohn’s clinical trials of Halcion.

On January 21, 1992, in response to the January 20, 1992, article in The New York Times, plaintiff, along with eleven others, filed this action. For various reasons that will be discussed below, only plaintiff Thomas Acito now remains. He is represented by eight law firms.

Plaintiff initially proposed a class period restricted only by the relevant statute of limitations, beginning January 21, 1989, and ending January 20, 1992 (“original class period”). However, in his reply brief to defendant’s brief opposing class certification, as well as at oral argument, plaintiff proposed shortening the class period by approximately four months. Plaintiff now suggests that the class period should run from January 21, 1989, through October 1, 1991 (“revised class period”). Plaintiff states that he chose the earlier date to end the class period because it will eliminate certain class conflicts and make the case more manageable. Because plaintiffs suggestion was not made in the form of a motion to amend the complaint, the class period under which plaintiff intends to proceed remains unclear to the court.

Plaintiff alleges defendants made various misrepresentations and omissions during the class period which fraudulently inflated the market price of Upjohn’s stock.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wilkof v. Carago Pharmaceutical Laboratories, Ltd.
280 F.R.D. 332 (E.D. Michigan, 2012)
In re Vitamin C Antitrust Litigation
279 F.R.D. 90 (E.D. New York, 2012)
Mendez v. Radec Corp.
260 F.R.D. 38 (W.D. New York, 2009)
Ross v. Abercrombie & Fitch Co.
257 F.R.D. 435 (S.D. Ohio, 2009)
Stanich v. Travelers Indemnity Co.
259 F.R.D. 294 (N.D. Ohio, 2009)
Cates v. Cooper Tire & Rubber Co.
253 F.R.D. 422 (N.D. Ohio, 2008)
In Re Scientific-Atlanta, Inc. Securities Litigation
571 F. Supp. 2d 1315 (N.D. Georgia, 2007)
In re Foundry Resins Antitrust Litigation
242 F.R.D. 393 (S.D. Ohio, 2007)
In re Organogenesis Securities Litigation
241 F.R.D. 397 (D. Massachusetts, 2007)
Olden v. LaFarge Corp.
472 F. Supp. 2d 922 (E.D. Michigan, 2007)
In re CMS Energy Securities Litigation
236 F.R.D. 338 (E.D. Michigan, 2006)
Abby v. City of Detroit
218 F.R.D. 544 (E.D. Michigan, 2003)
Bovee v. Coopers & Lybrand
216 F.R.D. 596 (S.D. Ohio, 2003)
Tilley v. TJX Companies, Inc.
212 F.R.D. 43 (D. Massachusetts, 2003)
Rockey v. Courtesy Motors, Inc.
199 F.R.D. 578 (W.D. Michigan, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
159 F.R.D. 473, 1994 U.S. Dist. LEXIS 19093, 1994 WL 735621, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ballan-v-upjohn-co-miwd-1994.